124 related articles for article (PubMed ID: 15057641)
1. Huntington's disease: which drugs might help patients?
Hannan AJ
IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
[TBL] [Abstract][Full Text] [Related]
2. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
Hannan AJ
Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
[TBL] [Abstract][Full Text] [Related]
3. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease.
van Dellen A; Grote HE; Hannan AJ
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1007-19. PubMed ID: 16445565
[TBL] [Abstract][Full Text] [Related]
4. Emerging drug therapies in Huntington's disease.
Mason SL; Barker RA
Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283
[TBL] [Abstract][Full Text] [Related]
5. Huntington's disease: the current state of research with peripheral tissues.
Sassone J; Colciago C; Cislaghi G; Silani V; Ciammola A
Exp Neurol; 2009 Oct; 219(2):385-97. PubMed ID: 19460373
[TBL] [Abstract][Full Text] [Related]
6. Genetic and environmental factors in the pathogenesis of Huntington's disease.
van Dellen A; Hannan AJ
Neurogenetics; 2004 Feb; 5(1):9-17. PubMed ID: 14745585
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
Nithianantharajah J; Hannan AJ
Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
[TBL] [Abstract][Full Text] [Related]
8. Emerging chemotherapeutic strategies for Huntington's disease.
Ryu H; Ferrante RJ
Expert Opin Emerg Drugs; 2005 May; 10(2):345-63. PubMed ID: 15934871
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for Huntington's disease.
Grimbergen YA; Roos RA
Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
[TBL] [Abstract][Full Text] [Related]
10. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.
Wong HK; Bauer PO; Kurosawa M; Goswami A; Washizu C; Machida Y; Tosaki A; Yamada M; Knöpfel T; Nakamura T; Nukina N
Hum Mol Genet; 2008 Oct; 17(20):3223-35. PubMed ID: 18658163
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
Butler R; Bates GP
Nat Rev Neurosci; 2006 Oct; 7(10):784-96. PubMed ID: 16988654
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: Histone modifications in Huntington's disease.
Sadri-Vakili G; Cha JH
Nat Clin Pract Neurol; 2006 Jun; 2(6):330-8. PubMed ID: 16932577
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models.
Browne SE
Ann N Y Acad Sci; 2008 Dec; 1147():358-82. PubMed ID: 19076457
[TBL] [Abstract][Full Text] [Related]
14. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
15. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
Wright DJ; Renoir T; Gray LJ; Hannan AJ
Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
[TBL] [Abstract][Full Text] [Related]
16. Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.
Winkler C; Gil JM; Araújo IM; Riess O; Skripuletz T; von Hörsten S; Petersén A
Brain Res Bull; 2006 Apr; 69(3):306-10. PubMed ID: 16564426
[TBL] [Abstract][Full Text] [Related]
17. Huntington's disease.
Grove M; Vonsattel JP; Mazzoni P; Marder K
Sci Aging Knowledge Environ; 2003 Oct; 2003(43):dn3. PubMed ID: 14586062
[TBL] [Abstract][Full Text] [Related]
18. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
19. Normal electrical properties of hippocampal neurons modelling early Huntington disease pathogenesis.
Shelbourne P; Coote E; Dadak S; Cobb SR
Brain Res; 2007 Mar; 1139():226-34. PubMed ID: 17291464
[TBL] [Abstract][Full Text] [Related]
20. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
